Literature DB >> 4580494

Decreased drug binding by serum albumin during renal failure.

D S Campion.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4580494     DOI: 10.1016/0041-008x(73)90312-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


× No keyword cloud information.
  14 in total

1.  Plasma protein binding of phenylbutazone during recovery from acute renal failure.

Authors:  M M Mussche; F M Belpaire; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

2.  Effect of endogenous metabolites on the binding of o-methyl red to human serum albumin [proceedings].

Authors:  C J Bowmer; W E Lindup
Journal:  Br J Pharmacol       Date:  1976-10       Impact factor: 8.739

3.  Factors affecting drug-protein binding in the plasma of newborn infants.

Authors:  S Wallace
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

4.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 5.  The binding of drugs to plasma proteins from patients with poor renal function.

Authors:  M M Reidenberg
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Protein binding of piretanide in normal and uraemic serum.

Authors:  H L Elliott; A F Ansari; B C Campbell; J R Lawrence
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

8.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

9.  Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.

Authors:  T J Dengler; G M Robertz-Vaupel; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Protein binding of salicylate in cutaneous hepatic porphyria.

Authors:  W H Steele; S W Boobis; M R Moore; A Goldberg; M J Brodie; D J Summer
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.